Latest Racing News

Encounter Resources has launched a rapid aircore drilling campaign at its Aileron project, targeting shallow, high-grade niobium and rare earth mineralisation to build on last year’s discoveries and resource base.

PointsBet has released a supplementary scheme booklet revealing an improved $1.20 per share cash offer from MIXI, alongside a postponed shareholder meeting now set for June 25. The deal, backed unanimously by the PointsBet board, faces final court and regulatory approvals.

Betr Entertainment has reaffirmed its superior $1.33 per share acquisition proposal for PointsBet, challenging the rival MIXI offer ahead of a crucial shareholder vote. With strong funding and synergy claims, Betr signals confidence that MIXI’s $1.20 bid will be rejected.

Aurum Resources reports significant shallow, wide gold intercepts at its Boundiali Gold Project in Côte d'Ivoire, reinforcing its 2025 drilling campaign and resource expansion ambitions.

IRIS Metals has reported promising high-grade lithium intersections from its Phase I drilling at the Edison Project in South Dakota, reinforcing its strategy to develop a centralized lithium processing hub in the US.

EMVision Medical Devices has secured a $5 million non-dilutive government grant to accelerate global commercialisation of its innovative First Responder portable brain scanner, aimed at revolutionising pre-hospital stroke and brain injury care.

Adavale Resources has been granted exploration license EL9785, including the high-grade Koh-I-Noor gold mine, adjacent to its Parkes Project in NSW. The company plans detailed exploration and a maiden drilling campaign in 2025 to unlock further mineral potential.

NH3 Clean Energy reports strong Pre-FEED results for its WAH2 clean ammonia project, highlighting robust economics and strategic partnerships while facing key risks around gas supply and funding.

PointsBet Holdings has secured Foreign Investment Review Board approval for MIXI Australia's proposed full acquisition, marking a key regulatory milestone in the takeover process.

ARC Funds Limited plans to acquire the remaining 36.51% stake in The Term Deposit Shop, offering new ARC shares in exchange. This move aims to consolidate ownership and accelerate growth leveraging TTDS’s $530 million Funds under Management.

PYC Therapeutics has secured Safety Review Committee approval to increase dosing in its clinical trial for a novel treatment targeting Autosomal Dominant Optic Atrophy, a rare blinding genetic disease. This milestone marks a significant step forward in the development of PYC-001, a first-in-class RNA therapy.

Radiopharm Theranostics has secured FDA Fast Track designation for RAD101, a novel imaging agent aimed at improving diagnosis of recurrent brain metastases. The move could speed development and regulatory review as the company advances its Phase 2 clinical trial.